117,662 research outputs found
Digital Trauma Load: from Online Videogaming to the new forms of digital social networking
No full text
Safety of escitalopram in pregnancy: a case series
No full textCesario Bellantuono, Francesca Bozzi, Laura Orsolini Psychiatric Unit and DEGRA Center, United Hospital and Academic Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Ancona, Italy Background: The aim of this paper is to report maternal and neonatal outcomes in pregnant women treated with escitalopram during pregnancy and breastfeeding. Methods: Women enrolled in the DEGRA Database at the Clinic of Affective Disorders in Pregnancy and Postpartum in Italy, treated during pregnancy with escitalopram and followed up throughout pregnancy, were included in this study. All patients provided written informed consent and the study was approved by the local ethics committee. Psychiatric diagnoses were assessed using the Structured Clinical Interview for DSM-IV (Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition) Axis I Disorders and symptoms were assessed using the Hamilton Rating Scale for Depression (17 items) and Hamilton Rating Scale for Anxiety (14 items). Clinical and sociodemographic characteristics as well as maternal and neonatal outcomes were recorded. Results: The case histories of seven pregnant women treated for depression and/or anxiety disorders with escitalopram were reported. Four women were also treated with benzodiazepines. All pregnancies were full-term and all newborns had normal Apgar scores. There were no major malformations or miscarriages following exposure to escitalopram. Mild withdrawal syndrome was reported only in a newborn who was also exposed to a benzodiazepine. Two infants exposed to escitalopram during breastfeeding did not show any health problems. Conclusion: Our experience with use of escitalopram in pregnant women did not reveal any maternal or neonatal concerns. However, considering the few cases analyzed and the paucity of published literature, no conclusions can be drawn on its safety profile in pregnancy and breastfeeding. Keywords: escitalopram, pregnancy, breastfeeding, major malformations, perinatal complication
Editorial: “No Words for Feelings, Yet!” Exploring Alexithymia, Disorder of Affect Regulation, and the “Mind-Body” Connection
No full text
Fasting insulinemia as a predictor of illness relapse in individuals with severe mental illness?
No full text
Psychopathological characterization of modern-type depression in subjects with Internet Gaming Disorder
No full textDigital therapeutics in depression and bipolar disorder: a comprehensive systematic review
No full textINTRODUCTION: Digital therapeutics (DTx) represent a novel approach to treat mood disorders like major depressive disorder (MDD) and bipolar disorder (BD). Treatment can usually be based on interventions such as cognitive behavioral therapy (CBT) and psychoeducation, and they can be relatively inexpensive and more easily accessible. However, upscaling DTx in clinical practice is relatively slow due to regulatory barriers, lack of sufficient clinical evidence, and patient nonadherence. EVIDENCE ACQUISITION: A systematic review following the PRISMA guidelines was carried out through MEDLINE/ PubMed and Scopus. All studies exploring the use of DTx for MDD and BD were assessed. While excluding studies not presenting any clinical results or not aimed at DTx but instead at general digital mental health (DMH) interventions. EVIDENCE SYNTHESIS: Initial search strategy produced 4598 papers, 24 of which have been selected and discussed. Most studies were conducted on MDD, rather than BD. Most frequently used approaches included CBT, psychoeducation and mindfulness. Most studies reported positive changes in mood symptoms, but only some of them provided information about the maintenance of these results in the long term. Among inhibitors in the acceptability of DTx were represented by limited real-world evidence, engagement issues and inconsistent regulatory environments. CONCLUSIONS: Using DTx for mood disorders shows great promise. Effective interventions that are accessible and modeled are feasible. However, to structurally incorporate DTx into standard clinical practice, there is the need to develop clear regulatory channels, improve user’s involvement and provide additional evidence of long-term efficacy
- …
